The Globoid Cell Leukodystrophy (Krabbe Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Globoid Cell Leukodystrophy (Krabbe Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Globoid Cell Leukodystrophy (Krabbe Disease) by 13 companies/universities/institutes. The top development phase for Globoid Cell Leukodystrophy (Krabbe Disease) is preclinical with seven drugs in that stage. The Globoid Cell Leukodystrophy (Krabbe Disease) pipeline has 12 drugs in development by companies and two by universities/ institutes. Some of the companies in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products market are: Polaryx Therapeutics, Vascumab and M6P Therapeutics.
The key targets in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products market include Galactocerebrosidase, Peroxisome Proliferator Activated Receptor Alpha, and Retinoic Acid Receptor RXR Alpha.
The key mechanisms of action in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline product include Galactocerebrosidase Replacement with four drugs in Preclinical. The Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products include four routes of administration with the top ROA being Oral and eight key molecule types in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products market including Small Molecule, and Gene Therapy.
Globoid Cell Leukodystrophy (Krabbe Disease) overview
Krabbe disease, also called globoid cell leukodystrophy, is a degenerative disorder caused by a deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, muscle spasms, loss of head control, vomiting, fever, irritability, and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsants, muscle relaxers) and providing supportive care.
For a complete picture of Globoid Cell Leukodystrophy (Krabbe Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
